SteadyMed

50 articles about SteadyMed

• Correvio Highlights Completion of SteadyMed Acquisition by United Therapeutics

  9/4/2018

  Correvio Pharma Corp. today highlighted that United Therapeutics (NASDAQ: UTHR) has completed its acquisition of SteadyMed Ltd., Correvio's partner and the licensor of Trevyent®.

• United Therapeutics Corporation Completes Acquisition Of SteadyMed Ltd.

  8/30/2018

  United Therapeutics Corporation today announced that it has closed the merger of SteadyMed Ltd. with a subsidiary of United Therapeutics.

• HSR Act Waiting Period Terminated for United Therapeutics' Acquisition of SteadyMed Ltd.

  7/20/2018

  The termination of the waiting period under the HSR Act satisfies one of the conditions to closing of the acquisition, which remains subject to other closing conditions, including the approval of the acquisition by SteadyMed's shareholders.

• United Therapeutics To Acquire SteadyMed Ltd.

  4/30/2018

  United Therapeutics Corporation and SteadyMed Ltd. announced today the signing of a definitive merger agreement under which United Therapeutics will acquire SteadyMed for $4.46 per share in cash at closing and an additional $2.63 per share in cash upon the achievement of a milestone related to the commercialization of Trevyent®.

• 

  United Therapeutics Strikes Deal for SteadyMed to Bolster PAH Pipeline

  4/30/2018

  Shares of SteadyMed Ltd. have skyrocketed more than 77 percent in premarket trading today after United Therapeutics announced it will acquire the company for a total of $216 million, including $75 million in contingent consideration.

• Cardiome Highlights Partner SteadyMed's Agreement With FDA on Pathway to Trevyent NDA Resubmission

  12/11/2017

  Cardiome plans to submit regulatory filings for Trevyent in Europe and Canada shortly following SteadyMed's NDA resubmission to the FDA.

• 

  SteadyMed Announces FDA Agreed Pathway to Trevyent NDA Resubmission

  12/8/2017

  No clinical trials are required for the NDA resubmission.

• SteadyMed Reports Third Quarter 2017 Financial Results and Provides Corporate Update

  11/13/2017

  Total operating expenses for the third quarter of 2017 were $5.4 million, compared to $8.0 million for the third quarter of 2016.

• SteadyMed Receives Notice Of Allowance For Its European Patent Relating To Enhanced Reduction Of Infusion-Site Pain

  10/12/2017

• SteadyMed Submits Type A Meeting Request Package To FDA

  9/28/2017

• FDA Rejects Bay Area SteadyMed's Pulmonary Arterial Hypertension NDA App

  8/31/2017

• SteadyMed Reports Second Quarter 2017 Financial Results And Provides Corporate Update

  8/11/2017

• SteadyMed Appoints Jeff Myers M.D. Ph.D. Vice President Of Medical Affairs

  7/31/2017

• Cardiome Pharma Corp.'s Partner SteadyMed Submits U.S. New Drug Application For TREVYENT For The Treatment Of Pulmonary Arterial Hypertension

  7/5/2017

• SteadyMed Raises Additional Capital From Key Institutional Shareholder

  5/26/2017

• SteadyMed Reports First Quarter 2017 Financial Results And Provides Corporate Update

  5/12/2017

• SteadyMed Receives USPTO Notice Of Allowance For Patent Related To Key Patchpump Technology

  5/2/2017

• Bay Area's SteadyMed Nabs $30 Million

  4/21/2017

• Cardiome Pharma Corp.'s Partner SteadyMed Announces Successful Completion Of Trevyent Clinical Validation Study

  4/6/2017

• SteadyMed Receives Favorable Ruling In Inter Partes Review Against United Therapeutics Patent

  4/3/2017